L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs.
The effects of L364718, a new CCK receptor antagonist, on CCK-8 stimulated pancreatic secretion and PP release were examined in three conscious dogs with pancreatic fistulas. L364718 (20 nmol/kg) caused a potent inhibition of CCK-8 stimulated pancreatic protein, amylase and trypsin secretion but not of volume and bicarbonate secretion. Release of PP by CCK was also significantly suppressed by L364718. The degree of inhibition by L364718 was dependent upon the amount of CCK-8 infused. This study demonstrates that L364718 acts as a potent antagonist of CCK's action on pancreatic enzyme secretion and PP release in dogs and suggests that this agent might be a useful tool for studying the physiological role of CCK in conscious animals.
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock 72205.
R
R
Hosotani
P
P
Chowdhury
D
D
McKay
P L
PL
Rayford
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D002766:Cholecystokinin / Q000502:physiology; D020109:Devazepide; D004285:Dogs; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000097:blood; D011506:Proteins / Q000378:metabolism; D012844:Sincalide / Q000037:antagonists & inhibitors*
D001570:Benzodiazepinones; D001639:Bicarbonates; D011506:Proteins; D010191:Pancreatic Polypeptide; D002766:Cholecystokinin; D020109:Devazepide; D012844:Sincalide